BioPharma Resources

Drug Trial Radar · NCT06318169

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,350

Planned (sponsor's estimate)

Start

Mar 13, 2024

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Interventions

  • PegozaferminBiological

    Subcutaneous injection

  • PlaceboOther

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52Time frame: Week 52
  2. Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52Time frame: Week 52
  3. Time to First Occurrence of Disease ProgressionTime frame: Up to 5 years

Locations

370 sites in 27 countries. Site status is shown where the registry gives one.

  • 89bio Clinical Study Site

    Birmingham, Alabama · Recruiting

  • 89bio Clinical Study Site

    Chandler, Arizona · Recruiting

  • 89bio Clinical Study Site

    Flagstaff, Arizona · Active not recruiting

  • 89bio Clinical Study Site

    Glendale, Arizona · Recruiting

  • 89bio Clinical Study Site

    Sun City, Arizona · Recruiting

  • 89bio Clinical Study Site

    Tucson, Arizona · Recruiting

  • 89bio Clinical Study Site

    Tucson, Arizona · Recruiting

  • 89bio Clinical Study Site

    Conway, Arkansas · Active not recruiting

  • 89bio Clinical Study Site

    Little Rock, Arkansas · Recruiting

  • 89bio Clinical Study Site

    North Little Rock, Arkansas · Recruiting

  • 89bio Clinical Study Site

    Canoga Park, California · Recruiting

  • 89bio Clinical Study Site

    Coronado, California · Recruiting

  • 89bio Clinical Study Site

    Escondido, California · Recruiting

  • 89bio Clinical Study Site

    Fountain Valley, California · Recruiting

  • 89bio Clinical Study Site

    Fresno, California · Recruiting

  • 89bio Clinical Study Site

    Gardena, California · Recruiting

  • 89bio Clinical Study Site

    Huntington Park, California · Withdrawn

  • 89bio Clinical Study Site

    Inglewood, California · Withdrawn

  • 89bio Clinical Study Site

    La Jolla, California · Recruiting

  • 89bio Clinical Study Site

    Lancaster, California · Recruiting

  • 89bio Clinical Study Site

    Long Beach, California · Recruiting

  • 89bio Clinical Study Site

    Los Angeles, California · Withdrawn

  • 89bio Clinical Study Site

    Montclair, California · Recruiting

  • 89bio Clinical Study Site

    Orange, California · Recruiting

  • 89bio Clinical Study Site

    Panorama City, California · Withdrawn

  • 89bio Clinical Study Site

    Pasadena, California · Recruiting

  • 89bio Clinical Study Site

    Poway, California · Recruiting

  • 89bio Clinical Study Site

    Rialto, California · Recruiting

  • 89bio Clinical Study Site

    Santa Ana, California · Withdrawn

  • 89bio Clinical Study Site

    Stanford, California · Recruiting

  • 89bio Clinical Study Site

    Victorville, California · Recruiting

  • 89bio Clinical Study Site

    Colorado Springs, Colorado · Withdrawn

  • 89bio Clinical Study Site

    Littleton, Colorado · Recruiting

  • 89bio Clinical Study Site

    Brandon, Florida · Recruiting

  • 89bio Clinical Study Site

    Clermont, Florida · Recruiting

  • 89bio Clinical Study Site

    Fort Myers, Florida · Recruiting

  • 89bio Clinical Study Site

    Hialeah Gardens, Florida · Recruiting

  • 89bio Clinical Study Site

    Homestead, Florida · Recruiting

  • 89bio Clinical Study Site

    Jacksonville, Florida · Recruiting

  • 89bio Clinical Study Site

    Jupiter, Florida · Recruiting

Showing 40 of 370 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.